Analyst Ratings for [NVS] Novartis AG

2/13/25	Downgrades	Buy Neutral	X
NVS Novartis AG UBS
2/12/25	Initiated	Underweight	X
NVS Novartis AG Morgan Stanley
12/4/24	Downgrades	Hold Reduce	X
NVS Novartis AG HSBC Securities
9/11/24	Downgrades	Buy Neutral	X
NVS Novartis AG BofA Securities
$135 $130
9/5/24	Downgrades	Buy Neutral	X
NVS Novartis AG Goldman
9/3/24	Downgrades	Buy Hold	X
NVS Novartis AG Jefferies
7/19/24	Downgrades	Buy Hold	X
NVS Novartis AG Deutsche Bank
5/30/24	Initiated	Buy	X
NVS Novartis AG Goldman
$120
2/23/24	Initiated	Market Perform	X
NVS Novartis AG BMO Capital Markets
$114
1/23/24	Initiated	Equal-Weight	X
NVS Novartis AG Morgan Stanley
$114
1/16/24	Resumed	Buy	X
NVS Novartis AG UBS
12/18/23	Downgrades	Buy Hold	X
NVS Novartis AG HSBC Securities
7/14/23	Initiated	Buy	X
NVS Novartis AG HSBC Securities
4/26/23	Upgrades	Hold Buy	X
NVS Novartis AG Deutsche Bank
1/26/23	Downgrades	Buy Neutral	X
NVS Novartis AG Citigroup
12/5/22	Upgrades	Hold Buy	X
NVS Novartis AG Stifel
9/15/22	Downgrades	Neutral Underperform	X
NVS Novartis AG Credit Suisse
9/14/22	Downgrades	Buy Hold	X
NVS Novartis AG Berenberg
5/9/22	Downgrades	Outperform Peer Perform	X
NVS Novartis AG Wolfe Research
1/10/22	Resumed	Buy	X
NVS Novartis AG Citigroup
3/22/21	Initiated	Mkt Perform	X
NVS Novartis AG Bernstein
3/10/21	Downgrades	Buy Hold	X
NVS Novartis AG Argus
2/1/21	Downgrades	Outperform Mkt Perform	X
NVS Novartis AG Cowen
$110 $105
1/15/21	Initiated	Buy	X
NVS Novartis AG Deutsche Bank
4/25/19	Upgrades	Neutral Buy	X
NVS Novartis AG Guggenheim
4/25/19	Upgrades	Hold Buy	X
NVS Novartis AG Liberum
4/10/19	Downgrades	Eq-Weight Underweight	X
NVS Novartis AG Morgan Stanley
1/2/19	Downgrades	Neutral Underweight	X
NVS Novartis AG JP Morgan
12/11/18	Resumed	Buy	X
NVS Novartis AG Jefferies
10/9/18	Initiated	Neutral	X
NVS Novartis AG Guggenheim
9/10/18	Upgrades	Underperform Buy	X
NVS Novartis AG BofA/Merrill
5/29/18	Downgrades	Buy Hold	X
NVS Novartis AG HSBC Securities
5/25/18	Upgrades	Underperform Neutral	X
NVS Novartis AG Credit Suisse

NVS Novartis AG

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.